Mitomycin solution for upper urinary tract cancer
Part of Cancer clinical trials.
This program provides access to a chemotherapy drug called mitomycin, given as a liquid into the kidney area, for people with a certain type of cancer in the upper urinary tract. It aims to see if this treatment can help when standard options are not suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be considered able to receive the drug by your doctor.
- Your doctor must believe the treatment may help you based on their medical judgment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a chemotherapy drug called mitomycin C directly into the bladder after a ureteroscopy can help prevent upper tract urothelial cancer from coming back or spreading. It is for people who are newly suspected of having this cancer and are about to have a diagnostic ureteroscopy.
This registry collects information about adults with upper tract urothelial cancer (UTUC) who received Jelmyto after it was approved. It helps doctors understand outcomes and real-world experience with Jelmyto.
This Phase 3 trial studies whether using gemcitabine (a chemotherapy medicine) in the urinary tract better prevents cancer from coming back than using a simple water wash. It involves people with upper tract urothelial carcinoma who are having curative surgery to remove the affected ureter or kidney tube.
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
This trial tests a combination of two chemotherapy drugs, gemcitabine and mitomycin, given directly into the kidney or ureter through a thin tube. It is for people with a high-risk but non-invasive form of upper urinary tract cancer that has not spread into deeper tissues.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
Hear when a new Urothelial Cancer of Renal Pelvis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.